LianBio Announces First Patient Treated In Phase 1 Trial Of SHP2 Inhibitor BBP-398 In Combination With Osimertinib In Patients With Non-Small Cell Lung Cancer With EGFR Mutations
Portfolio Pulse from Benzinga Newsdesk
LianBio (NASDAQ:LIAN) has announced the first patient has been dosed in its Phase 1 clinical trial of BBP-398, an investigational SHP2 inhibitor, in combination with AstraZeneca's osimertinib, for the treatment of patients with non-small cell lung cancer (NSCLC) with EGFR mutations. The trial is designed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of BBP-398 in combination with osimertinib. BBP-398 is being developed for difficult-to-treat cancers and was founded through a collaboration between BridgeBio and The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division.
August 04, 2023 | 2:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
LianBio has started a Phase 1 trial of BBP-398, a potential treatment for NSCLC. The trial's success could boost the company's stock.
The initiation of a Phase 1 trial is a significant milestone for LianBio. If the trial is successful, it could lead to a potential new treatment for NSCLC, which could significantly boost the company's stock. However, the trial is still in its early stages, and there is a risk that it may not be successful.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100